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Peroxisome proliferator-activated receptor g coacti-
vator-1 b (PGC-1b) is known to be a transcriptional
coactivator for SREBP-1, the master regulator of
hepatic lipogenesis. Here, we evaluated the role of
PGC-1b in the pathogenesis of fructose-induced
insulin resistance by using an antisense oligonucle-
toide (ASO) to knockdown PGC-1b in liver and
adipose tissue. PGC-1bASO improved the metabolic
phenotype induced by fructose feeding by reducing
expression of SREBP-1 and downstream lipogenic
genes in liver. PGC-1b ASO also reversed hepatic
insulin resistance induced by fructose in both basal
and insulin-stimulated states. Furthermore, PGC-1b
ASO increased insulin-stimulated whole-body
glucose disposal due to a threefold increase in
glucose uptake in white adipose tissue. These data
support an important role for PGC-1b in the patho-
genesis of fructose-induced insulin resistance and
suggest that PGC-1b inhibition may be a therapeutic
target for treatment of NAFLD, hypertriglyceridemia,
and insulin resistance associated with increased de
novo lipogenesis.
INTRODUCTION
Insulin resistance is a common feature of the metabolic
syndrome and type 2 diabetes mellitus (T2DM). Both have
reached epidemic proportions worldwide (Zimmet et al., 2001)
with the global adoption of the westernized diet along with
increased consumption of fructose, stemming from the wide
and increasing use of high-fructose corn syrup sweeteners (El-
liott et al., 2002; Basciano et al., 2005). It is well established
that fructose is more lipogenic than glucose, and high-fructose
diets have been linked to hypertriglyceridemia, nonalcoholic
fatty liver disease (NAFLD), and insulin resistance (Daly et al.,252 Cell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc.1997; Sleder et al., 1980; Havel, 2005; Petersen et al., 2007).
Despite a clear relationship between fructose and increased
hepatic lipogenesis, themechanisms responsible for this associ-
ation remain poorly defined.
Hepatic lipogenesis is regulated by the action of sterol regula-
tory element-binding protein (SREBP) transcription factors,
especially SREBP-1c, the principal inducer of hepatic lipogenic
gene expression (Shimano et al., 1997). Dietary fructose, per
se, activates lipogenesis partly through inducing expression of
SREBP-1 (Nagai et al., 2002). Among strains of inbred mice,
a genetic polymorphism within the SREBP-1c promoter region
underlies a differential sensitivity to fructose-induced lipid
synthesis, further suggesting that this transcription factor medi-
ates the lipogenic effects of fructose (Nagata et al., 2004).
Although there is evidence linking induction of SREBP-1c to
fructose-induced lipogenesis in vivo, the mechanism respon-
sible for fructose-induced alterations in SREBP-1c transcription
remains unknown.
Recent studies implicate the peroxisome proliferator-acti-
vated receptor gamma (PPARg) coactivator-1 (PGC-1) family in
regulating liver glucose and lipid metabolism. Though initially
described as a coactivator of PPARg (Lin et al., 2002), PGC-1
is now recognized to coactivate multiple other transcription
factors. Through these interactions, they can coordinate both
hepatic glucose and lipid metabolism, the former via forkhead
transcription factor-1 (FOXO1) (Puigserver et al., 2003); hepato-
cyte nuclear factor 4 alpha (HNF4a) (Rhee et al., 2003) and my-
ocyte enhancer factor-2 (MEF-2) (Michael et al., 2001), the latter
via peroxisome proliferator-activated receptor a (PPARa) (Vega
et al., 2000); liver X receptor (LXR) (Lin et al., 2005); and SREBP
(Lin et al., 2005). PGC-1b, but not PGC-1a, activates the expres-
sion of genes involved in lipogenesis and triglyceride secretion
via direct coactivation of SREBPs (Lin et al., 2005). Thus, PGC-
1b, a regulator of both carbohydrate and lipid metabolism, is
poised to play a pivotal role in fructose-induced lipogenesis.
We hypothesized that PGC-1b mediates fructose-induced
lipogenesis via upregulation of SREBP-1c, and knockdown
of PGC-1b would prevent this from occurring. To test this
hypothesis, we knocked down the expression of PGC-1b using
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PGC1b ASO Prevents Insulin Resistance by Fructoseantisense oligonucleotides (ASOs) in chronically (4 weeks)
fructose-fed rats. ASOs are ideal for these studies, as they can
target both liver and adipose tissues in adult animals. Our studies
reveal an important role for PGC-1b in the pathogenesis of
fructose-induced insulin resistance and suggest that PGC-1b
inhibition may be a therapeutic target for treatment of NAFLD,
hypertriglyceridemia, and insulin resistance.
RESULTS
PGC-1b ASO Decreases PGC-1b Expression
in Rat Livers and White Adipose Tissue
Rats were divided into two diet groups and two ASO treatment
groups. They received either a regular chow diet, which provided
60% calories from carbohydrates, predominantly in the form of
starch, or a high-fructose diet that provided 66.8% calories
from fructose. Within each diet group, rats were treated with
either control ASO or PGC-1b ASO at 25 mg/kg body weight
twice weekly for 4 weeks. Caloric intake and weight gain were
similar in all treated groups. Compared to control ASO, PGC-
1b ASO treatment reduced PGC-1b mRNA expression by
approximately 75% in the liver (Figure 1A) and 70% in the white
adipose tissue (WAT) (Figure 1B). The reduction in mRNA with
PGC-1b ASO translated into a similar reduction in PGC-1b
protein (Figures 1C and 1D). In contrast, PGC-1b ASO did not
significantly reduce expression of PGC-1b in either brown
adipose tissue (BAT) or skeletal muscle (Figures 1E and 1F).
Finally, rats remained free of hepatotoxicity, as reflected by the
absence of alanine amino transaminase elevation in all four
groups (Table 1).
PGC-1b ASO Improves Metabolic Parameters Induced
by High-Fructose Feeding
To evaluate the effect of knocking down PGC-1b on whole-body
physiology, we performed detailed metabolic characterization,
including measures of morphology and serum chemistry as
well as glucose and lipid kinetics. As shown in Table 1, epidid-
ymal fat mass and plasma concentrations of glucose, triglyc-
eride, fatty acids, insulin, and leptin were significantly higher in
the high-fructose-fed rats. Knockdown of PGC-1b protected
rats from all these fructose-induced changes. Compared with
the rats fed high-fructose diet, the plasma glucose and insulin
levels were significantly lower in PGC-1b ASO-treated rats,
12% and 37%, respectively. The plasma triglyceride and leptin
levels and epididymal fat mass were also significantly lower:
40%, 50%, and 13%, respectively. On the other hand, plasma
concentrations of total cholesterol, HDL cholesterol, and b-hy-
droxybutyrate were significantly higher in PGC-1b ASO-treated
rats: 58%, 63%, and 11%, respectively. Finally, there were no
differences in plasma concentrations of glucagon, adiponectin,
or retinol-binding protein 4 (RBP4).
The changes in plasma triglyceride and cholesterol concentra-
tions seen with PGC-1b ASO treatment prompted further anal-
ysis of their respective pathways. Using primary hepatocytes,
we quantified the impact of PGC-1b inhibition on lipid and sterol
synthesis in vitro. Specifically, the synthesis was assessed by
measuring the incorporation of [14C]acetic acid into fatty acid
and cholesterol. PGC-1b ASO inhibited the synthesis of fatty
acids (Figure 2A) but not of cholesterol (Figure 2B). TheCdecreased lipid synthesis in vitro was reflected in vivo, where
PGC-1b ASO prevented the accumulation of liver triglyceride
observed with high-fructose feeding (Figure 2C).
PGC-1b ASO Reduces Lipogenic Gene Expression
Gene expression was profiled by RT-qPCR to determine what
genes were affected by PGC-1b ASO in fructose-fed rats. Under
fasting condition, SREBP-1c and -1a mRNA levels were similar
among the four groups (Figures 3A and 3B). Though with
refeeding, SREBP-1c expression increased in all groups, and
SREBP-1a expression increased in high-fructose-fed groups;
there were marked differences in the degree of induction.
SREBP-1c and -1a expression increased 5 times and 1.5 times,
respectively, with feeding. This exaggerated induction of
SREBP-1c by fructose was attenuated 40% with PGC-1b ASO
treatment (Figure 3A). The changes in SREBP-1a/-1c expression
were confirmed by quantifying SREBP-1 protein with western
blot analysis (Figure 3C). The decreased induction of SREBP-1
with PGC-1b ASO was reflected in decreased activation of fatty
acid synthase (FAS) gene by fructose (Figure 3D).
It has been reported that rat SREBP-1c promoter contains
binding sites for SREBP (Cagen et al., 2005) and LXR (Dif
et al., 2006), which are both coactivated by PGC-1b (Lin et al.,
2005). We next examined whether the binding of SREBP-1 or
LXR to the SREBP-1c promoter was affected by PGC-1b ASO
treatment. Formaldehyde treatment of fresh liver samples was
used to cross link the transcription factors with the chromosomal
DNA. Chromatin immunoprecipitation (ChIP) assays were
performed using anti-SREBP-1 (H-160) or anti-LXRa/b (S-20)
antibodies to immunoprecipitate fragments of DNA where there
was interaction. Figure 3E shows the amplification by PCR
(33 cycles) of a specific portion of the proximal promoter of the
SREBP-1c gene. We quantified the PCR products using real-
time PCR and confirmed that the amplification of the negative
control using normal rabbit IgG was less than 0.05% of that of
the input sample (data not shown). Moreover, we also confirmed
that there was no difference in LXR mRNA and protein expres-
sion among all four groups (Table S1 and data not shown).
When rats were refed with a high-fructose diet, there was
a marked increase in the association of both SREBP-1 and
LXRa/b with the SREBP-1c promoter. PGC-1b ASO decreased
both bindings. These data were consistent with SREBP-1c
mRNA (Figure 3A) and protein (Figure 3C) expressions. Thus,
the ability of fructose to activate a program of lipogenesis via
SREBP-1 was inhibited by PGC-1b ASO.
While PGC-1b ASO decreased liver and plasma triglyceride
concentrations in fructose-fed rats, plasma cholesterol concen-
trations were increased in both diet groups (Table 1). We also
measured the expression of key genes that regulate cholesterol
metabolism. Neither high-fructose feeding nor PGC-1b ASO
treatment increased expression of SREBP-2 or downstream
targets such as HMG-CoA reductase (HMGCoAR) and LDL-
receptor (Table S1). LXRa, a nuclear receptor that balances
cholesterol and bile metabolism (Kalaany et al., 2005), is also
coactivated by PGC-1a/-1b (Lin et al., 2005). Although LXRa
expression was unchanged by either diet or ASO treatment
(Table S1), target gene cholesterol-7a-hydroxylase (CYP7A1)
protein expression was significantly decreased in all PGC-1b
ASO-treated groups independent of diet (Figure 3F). CYP7A1ell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc. 253
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PGC1b ASO Prevents Insulin Resistance by FructoseFigure 1. PGC-1b ASO Treatment Is Effective and Well Tolerated
(A–F) The amount of PGC-1b mRNA was determined by quantitative RT-qPCR after 4 weeks of feeding with fructose and treatment with a control ASO and
an ASO against PGC-1b (PGC-1b ASO) in liver (A), epididymal WAT (B), BAT (E), and soleus muscle (F). PGC-1b protein levels are shown in liver (C) and WAT
(D). Two separate samples are shown for each group fraction. Data are means ± SEM. Data are expressed as relative to expression in regular chow-fed control
ASO-treated rats (n = 7–9 rats per treatment group). #p < 0.05, ##p < 0.01, ###p < 0.001 versus regular chow-fed control ASO-treated rats; *p < 0.05, **p < 0.01,
***p < 0.001 versus high-fructose-fed control ASO-treated rats.converts cholesterol into 7a-hydroxycholesterol and is respon-
sible for the rate-limiting step in the classical bile acid synthesis
pathway. Thus, CYP7A1 mediates clearance of cholesterol from
the circulation, and it is possible that the decrease in CYP7A1
protein expression is responsible for the observed increased254 Cell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc.concentrations of cholesterol in the PGC-1b ASO-treated
rats. Some other target genes of LXR (SR-B1, ABCG8) had
decreased transcription by PGC-1b ASO treatment (Table S1);
however, there was no difference in protein expression (data
not shown).
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PGC1b ASO Prevents Insulin Resistance by FructoseTable 1. Physiologic and Plasma Parameters in Control and PGC-1b ASO-Treated Rats
Regular chow Fructose diet
Control ASO PGC-1b ASO Control ASO PGC-1b ASO
Physiologic parameters
Body weight (g) 356 ± 6 344 ± 7 363 ± 5 343 ± 6
Epididymal fat mass (g) 3.82 ± 0.21 4.57 ± 0.36d 6.16 ± 0.40c 5.33 ± 0.18a
Plasma metabolites
Glucose (mg/dl) 117.5 ± 1.8 112.9 ± 1.7f 129.2 ± 2.6c 113.3 ± 1.6f
Triglyceride (mg/dl) 49.2 ± 4.1 52.4 ± 5.6e 92.0 ± 10.4c 55.2 ± 3.9e
Total cholesterol (mg/dl) 64.1 ± 4.1 88.1 ± 5.8b,d 68.9 ± 3.1 108.7 ± 5.4c,f
HDL cholesterol (mg/dl) 23.1 ± 0.9 32.1 ± 1.4b,d 25.3 ± 0.9 41.3 ± 2.3c,f
Nonesterified fatty acid (meq/l) 1.04 ± 0.06 1.22 ± 0.10 1.50 ± 0.12b 1.39 ± 0.10
b-hydroxybutyrate (mmol/l) 0.84 ± 0.05 1.18 ± 0.07a 1.11 ± 0.08 1.23 ± 0.08b
ALT (units/l) 47.1 ± 5.2 55.8 ± 6.0 38.9 ± 3.8 43.8 ± 3.4
Plasma hormones and adipocytokines
Insulin (mU/l) 10.4 ± 1.1 8.0 ± 1.4f 19.8 ± 2.1c 12.5 ± 1.0e
Glucagon (pg/ml) 46.9 ± 8.8 51.9 ± 5.4 40.5 ± 5.0 54.6 ± 5.4
Adiponectin (mg/ml) 2.82 ± 0.07 3.11 ± 0.13 3.15 ± 0.04 2.78 ± 0.11
Leptin (ng/ml) 1.02 ± 0.19 0.74 ± 0.15 1.82 ± 0.28 0.91 ± 0.12d
RBP4 (mg/ml) 43.5 ± 4.33 35.1 ± 3.92 45.7 ± 2.99 53.2 ± 4.24
Data are means ± SEM; n = 25 rats in each group.
ap < 0.05, bp < 0.01, and cp < 0.001 versus regular chow-fed control ASO-treated rats.
dp < 0.05, ep < 0.01, and fp < 0.001 versus high-fructose-fed control ASO-treated rats.PGC-1b ASO Protects High-Fructose-Fed but Not
Regular Chow-Fed Rats fromHepatic Insulin Resistance
PGC-1b ASO lowered fasting plasma glucose and insulin
concentrations in high-fructose-fed rats, suggesting improved
insulin sensitivity. We performed hyperinsulinemic-euglycemic
clamps in order to further understand the mechanisms of
improved insulin sensitivity. The basal rate of hepatic glucose
production (HGP) was significantly increased in high-fructose-
fed rats compared with regular chow-fed rats (Figure 4A). In fruc-
tose-fed rats, PGC-1b ASO treatment decreased HGP along
with plasma glucose and insulin concentrations.
Underhyperinsulinemic-euglycemicconditions,plasma insulin
concentrations were raised to 80 mU/l while plasma glucose
levels were maintained at approximately 5.5 mM in all groups
with a variable infusion of glucose (data not shown). Under these
conditions, HGPwas significantly higher in high-fructose-fed rats
(Figure 4B). PGC-1bASO treatment improved the ability of insulin
to suppress HGP in high-fructose-fed rats (Figure 4B).
We measured hepatic diacylglycerol (DAG), which has previ-
ously been associated with insulin resistance (Samuel et al.,
2004). In the basal state, DAG concentration was markedly
increased in high-fructose-fed rats (Figure 4C). PGC-1b ASO
treatment decreased DAG concentrations 60% (Figure 4C). In
the past, we have shown that DAG accumulation leads to
PKC3 activation (Samuel et al., 2007). The decreased DAG
concentrations seen with PGC-1b ASO were associated with
decreased PKC3 membrane to cytosol ratio (Figure 4E) and
increased hepatic Akt activity (Figure 4G).
In contrast with fructose feeding, HGP was paradoxically
higher in the regular chow-fed PGC-1b ASO-treated rats
(Figure 4B). Hepatic DAG concentration was significantly
increased, 2-fold, in regular chow-fed PGC-1b ASO-treatedCrats after insulin stimulation (Figure 4D). PKC3 membrane to
cytosol ratio was increased over six times in regular chow-fed
PGC-1b ASO-treated rats after insulin stimulation (Figure 4F).
The unexpected hepatic insulin resistance seen in the regular
chow groups is consistent with previous studies in mice lacking
exons 3–4 of the PGC-1b gene (PGC-1bE3,4/E3,4mice) (Vianna
et al., 2006). In these mice, defects in mitochondrial oxidative
capacity were implicated in the development of insulin resis-
tance. PGC-1b has been reported to coactivate both PPARa
(Lin et al., 2003), which plays a key role in control of fatty acid
oxidation, and nuclear respiratory factor (NRF)-1 (Wu et al.,
1999), which regulates proteins required for mitochondrial func-
tion (Scarpulla, 2002). PGC-1b ASO significantly decreased
PPARa mRNA expression and its target genes LCAD, MCAD,
and CPT1a in both regular chow-fed and high-fructose-fed rats
by 30% (Figures 5A and 5B). NRF-1 mRNA expression was
significantly decreased by 40% (Figure 5C). Consistent with this
reduction, mitochondrial copy numbers were also significantly
reduced by 30% in PGC-1b ASO-treated groups (Figure 5D).
Additionally, PGC-1b ASO decreased expressions of ATPase
synthase subunit 6 (ATP6), a mitochondrial encoded gene, and
cytochromeC,anuclearencodedmitochondrial gene (Figure5E).
In order to determine whether PGC-1b ASO has any effect on
other diet-induced insulin resistance models, we tested PGC-1b
ASO on rats fed a high-fat diet. Though both fasting plasma
glucose and insulin concentrations were significantly decreased
in PGC-1b ASO-treated high-fat-fed rats (Figures S1A and S1B),
there was no difference in HGP both under basal and insulin-
stimulated conditions (Figure S1C). In addition, the degree of
induction of SREBP-1c with refeeding was less than that
observed compared to high-fructose-fed rats. PGC-1b ASO
did not decrease SREBP-1c mRNA expression (Figure S1E).ell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc. 255
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PGC1b ASO Prevents Insulin Resistance by FructoseFigure 2. PGC-1b ASO Treatment Reduces Fatty Acid Synthesis In Vitro and Triacylglycerol Content In Vivo
(A and B) Synthesis of fatty acids (A) and sterols (B) in rat hepatocytes. #p < 0.05 versus control ASO.
(C) Hepatic triglyceride content. Data are means ± SEM (n = 11–14 rats per treatment group). #p < 0.01 versus regular chow-fed control ASO-treated rats;
*p < 0.05 versus high-fructose-fed control ASO-treated rats.The unchanged expression of SREBP-1c was reflected by
unchanged DAG accumulation in liver (Figure S1E).
PGC-1b ASO Treatment Improves Adipose Insulin
Action in High-Fructose-Fed Rats
Insulin-stimulated whole-body glucose disposal was decreased
by 50% in the high-fructose-fed rats compared to the regular
chow-fed rats (Figure 6A). PGC-1b ASO rescued the fructose-
induced insulin resistance, as shown by the 90% increase in
insulin-stimulated whole-body glucose uptake.
In order to determine the organs’ response to the increased
insulin-stimulated glucose uptake seen in high-fructose-fed
PGC-1b ASO-treated rats, we assessed [14C]2-deoxyglucose
uptake in muscle and adipose tissue. There was no significant
increase in either muscle or BAT [14C]2-deoxyglucose uptake
(Figures 6B and 6C). However, in high-fructose-fed PGC-1b
ASO-treated rats, glucose uptake in the epididymal WAT was
increased nearly 4-fold compared with that in the other three
groups (Figure 6D). The augmented adipose insulin sensitivity
is corroborated by a decreased plasma fatty acid concentration
during the hyperinsulinemic-euglycemic clamps (data not
shown). To further explore the mechanism for the increased
WAT glucose uptake, we first examined the gene expression of
PPARg and its target genes in epididymal WAT. Surprisingly,
the expression of PPARgwas decreased by 50%, and adipocyte256 Cell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc.protein 2 (aP2), adiponectin, and acyl-CoA synthetases (ACS)
were decreased in PGC-1b ASO-treated groups (Table S2).
PGC-1b also induces mRNA expression of GLUT4 in cultures
of primary rat skeletal muscle cells (Mortensen et al., 2006). In
the present study, GLUT4 mRNA in WAT was decreased by
50% in PGC-1b ASO-treated groups (Table S2). In contrast,
the protein expression in both total tissue lysate and plasma
membrane was increased 2-fold in only PGC-1b ASO-treated
high-fructose-fed rats (Figures 6E and 6F), consistent with the
result of 2-deoxyglucose uptake in WAT. There were no differ-
ences in the expression of other glucose transporters (GLUT1
and GLUT5 [known as a fructose transporter]) (data not shown).
The discordance between GLUT4 mRNA and protein could
possibly be explained by increased expression of associated
proteins that regulate GLUT4 trafficking and stability. However,
we were unable to detect any changes in the expression of these
proteins that accounted for the increased WAT GLUT4 protein
content in the PGC-1b ASO-treated rats (Table S2). Furthermore,
one report suggests that GLUT4 can be degraded by calpain-2
(Otani et al., 2004). But calpain-1/-2 activity was similar across
all groups (data not shown).
Interestingly, this amelioration of diet-induced insulin resis-
tance by PGC-1b ASO was not seen in high-fat-fed rats
(Figure 6A). Consistent with this result, GLUT4 protein expres-
sion in WAT was not increased in high-fat-fed rats (Figure S1F).
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PGC1b ASO Prevents Insulin Resistance by FructoseFigure 3. PGC-1b ASO Treatment Reduces Expression of Lipogenic Genes in Liver
(A and B) Total mRNA was isolated from fasted and fed liver and quantified using primers for SREBP-1c (A) and -1a (B).
(C) Representative immunoblots of liver homogenates from liver in fed state. Two separate samples are shown for each group.
(D) Total mRNA was isolated from fasted and fed liver and quantified using primers for key enzymes in FAS.
(E) ChIP assay of SREBP-1c gene promoter. After cross linking chromatin DNA to the interacting proteins, specific immunoprecipitation with anti-SREBP-1 or
anti-LXRa/b antibodies was performed as described in Experimental Procedures. PCR products of the SREBP-1c promoter were analyzed after PCR amplifica-
tion (33 cycles). The lower part of the figure shows verification of the quantitative aspect of the PCR amplification using serial dilutions of the input.
(F) Liver gene expression of CYP7A1. Data aremeans ± SEM (n = 7–9 rats per treatment group). Solid bars represent fasted values, and striped bars represent fed
values. #p < 0.05, ##p < 0.01, ###p < 0.001 versus regular chow-fed control ASO-treated rats; *p < 0.05, **p < 0.01, ***p < 0.001 versus high-fructose-fed control
ASO-treated rats.Cell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc. 257
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PGC1b ASO Prevents Insulin Resistance by FructoseFigure 4. PGC-1b ASO Treatment Protects against Fructose-Induced Hepatic Insulin Resistance but Induces Hepatic Insulin Resistance
in Regular Chow-Fed Rats
(A and B) Rate of basal (A) and clamp (B) endogenous glucose production.
(C and D) Hepatic total DAG obtained from basal (C) and clamp (D) liver.
(E and F) Representative western blots showing basal (E) and clamp (F) membrane to cytosol fractions ratio for PKC3. The relative densities of the bands in the
membrane fraction were compared with the cytosol fraction to derive a quantifiable measure of activation.
(G) Basal Akt activity in liver. Data are means ± SEM (n = 6–20 rats per treatment group) #p < 0.05 versus regular chow-fed control ASO-treated rats; *p < 0.05
versus high-fructose-fed control ASO-treated rats.DISCUSSION
It is becoming increasingly clear that PGC-1b plays an important
role as a regulator of both carbohydrate and lipid metabolism. In258 Cell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc.the present study, we evaluated themetabolic effects of PGC-1b
knockdown in rats with fructose-induced insulin resistance. Here
we show that hepatic de novo lipogenesis and hepatic triglyc-
eride synthesis induced by fructose are both decreased by
Cell Metabolism
PGC1b ASO Prevents Insulin Resistance by FructoseFigure 5. PGC-1b ASO Treatment Reduces Genes Involved with Mitochondrial Fatty Acid Oxidation, Biogenesis, and Function
(A and B) Liver gene expression of PPARa (A) and target enzymes in fatty acid oxidation (B).
(C–E) Liver gene expression of NRF-1 (C) and target enzymes in mitochondrial oxidative phosphorylation (E). mtDNA copy number is determined by real-time
qPCR using primers for mitochondrial encoded gene (ATP6) and nuclear encoded gene (b-actin) (D). mtDNA copy number is calculated as the ratio of ATP6
to b-actin. Data are means ± SEM (n = 6–8 rats per treatment group). #p < 0.05, ##p < 0.01, ###p < 0.001 versus regular chow-fed control ASO-treated rats;
*p < 0.05, **p < 0.01 versus high-fructose-fed control ASO-treated rats.PGC-1b ASO treatment. Furthermore, we show that knockdown
of PGC-1b prevents fructose-induced hypertriglyceridemia and
hepatic and peripheral insulin resistance.
PGC-1b has been reported to coactivate its partners through
augmentation of their transcriptional activity (Lin et al., 2005).
Though initially described to pair with PPARg, the number
of partners for PGC-1 transcription factors is rapidly growing.
One of its partners is SREBP-1c. The transcriptional control
of this key regulator of lipogenesis is complex. It has been
reported that rat and human SREBP-1c promoter contains
binding sites for both SREBP itself (Cagen et al., 2005) and
LXR (Dif et al., 2006), which are both regulated by PGC-1b (Lin
et al., 2005).
The ChIP assay data showed a marked increase in the associ-
ation of both SREBP-1 and LXRa/bwith the SREBP-1c promoter
on a high-fructose diet. The bindings were both decreased by
PGC-1b ASO treatment. Undoubtedly, the binding of SREBP-1
to SREBP-1c promoter might be reflected with the amount of
SREBP-1 total protein, but the binding of LXR to SREBP-1c
promoter was also decreased by PGC-1b ASO treatment. LXRprotein was unchanged between all groups, implying that the
decreased binding to the SREBP-1c promoter was due to the
decreased coactivation with PGC-1b. Thus, these data suggest
that PGC-1b ASO treatment reduces SREBP-1c expression by
decreased coactivation of LXR and SREBP.
Consistent with the reduction of SREBP-1 expression, FAS,
a target lipogenic gene of SREBP-1, was downregulated in high-
fructose-fed PGC-1b ASO-treated rats. This likely accounted for
the observeddecrease in hepatic de novo lipogenesis and hepatic
triglyceride content and reductions in hypertriglyceridemia in the
high-fructose-fed PGC-1b ASO-treated rats. Supporting these
observations, we found that in vitro hepatic triglyceride synthesis
was significantly inhibited in primary rat hepatocytes by PGC-1b
ASO treatment.
Knockdown of PGC-1b in liver protected rats from fructose-
induced hepatic insulin resistance. This protection from fruc-
tose-inducedhepatic insulin resistancecouldmostlybeattributed
to reduction in hepatic lipogenesis resulting in reduced hepatic
DAG content and decreased PKC3 activation. These data were
also reflected in Akt activity.Cell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc. 259
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PGC1b ASO Prevents Insulin Resistance by FructoseFigure 6. PGC-1b ASO Treatment Improves Peripheral Insulin Sensitivity Due to an Increase in White Adipose Tissue Glucose Uptake
in High-Fructose-Fed Rats
(A) Rate of insulin-stimulated whole-body glucose uptake.
(B) Soleus [14C]2-deoxyglucose (2DG) uptake.
(C) BAT 2DG uptake.
(D) Epididymal WAT 2DG uptake.
(E and F) Western blotting of extract from total tissue (E) and plasma membrane fraction (F) using the GLUT4-specific mouse monoclonal antibody (1F8). Two
separate samples are shown for each group fraction. Data are means ± SEM (n = 6–20 rats per treatment group). #p < 0.001 versus regular chow-fed control
ASO-treated rats; *p < 0.05, ***p < 0.001 versus high-fructose-fed control ASO-treated rats.260 Cell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc.
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ASO on the liver differed in the regular chow- and high-fruc-
tose-fed rats. In regular chow-fed rats, PGC-1b ASO induced
slight but significant reductions in insulin suppression of HGP.
These reductions in insulin responsiveness could be attributed
to decreased mitochondrial fatty acid oxidation resulting in
increased DAG content and to increased PKC3 activation result-
ing in decreased insulin signaling (Samuel et al., 2007). PGC-1s
have been reported to coactivate both PPARa and NRF-1.
PPARa plays a key role in the transcriptional control of genes
encoding mitochondrial fatty acid oxidation enzymes such as
LCAD and MCAD. NRFs regulate expression of mitochondrial
transcription factor A (Tfam), a nuclear-encoded transcription
factor essential for replication, maintenance, and transcription
of mitochondrial DNA. NRFs also control the expression of
nuclear genes encoding respiratory chain subunits and other
proteins required for mitochondrial function (Scarpulla, 2002).
PGC-1b ASO decreased expression of genes encoding fatty
acid oxidation and oxidative phosphorylation as well as mito-
chondrial copy number, suggesting that PGC-1b is required in
liver for normal expression of genes encoding fatty acid oxida-
tion and oxidative phosphorylation. These results are consistent
with previous studies in PGC-1bE3,4/E3,4 mice (Vianna et al.,
2006) and LCAD knockout mice, which both develop hepatic
steatosis and hepatic insulin resistance due to decreased
hepatic fat oxidation, resulting in increased hepatic DAG content
and increased PKC3 activation (Zhang et al., 2007).
PGC-1b ASO also prevented fructose-induced insulin resis-
tance in peripheral tissue. This preservation of insulin respon-
siveness could be attributed largely to a 3-fold increase in
insulin-stimulated WAT glucose uptake. Since the PGC family
members are known coactivators of PPARs, we examined the
expression of PPARg and its target genes. The expression of
PPARg itself, as well as of key target genes, was reduced with
PGC-1b ASO treatment and could not explain the observed
improvements in insulin action.
We next investigated GLUT4 expression and found that
the GLUT4 protein expression in WAT was increased more than
4-fold in the high-fructose-fed PGC-1b ASO-treated rats. This
was compatible with our findings in the glucose uptake, although
the mRNA expression of GLUT4 was surprisingly decreased by
PGC-1b ASO treatment. A similar dissociation between GLUT4
protein and mRNA expression has been reported by Otani et al.
(Otani et al., 2004). We believe this result may reflect enhanced
stability of GLUT4 protein, leading to its accumulation. However,
in the present study, we did not find any explanations in the gene
expression of GLUT4 trafficking proteins. Further studies are
required to explain why the increases of 2-deoxyglucose uptake
and GLUT4 protein expression were seen in only high-fructose-
fed PGC-1b ASO-treated rats.
We tested PGC-1b ASO on rats fed a high-fat diet to under-
stand if the protection from diet-induced insulin resistance was
specific for high-fructose diet. PGC-1b ASO failed to ameliorate
both hepatic and peripheral insulin resistance in high-fat-fed
rats. The degree of SREBP-1 induction with high-fat diet was
less than that with high-fructose diet, and PGC-1b ASO did not
affect the SREBP-1 mRNA expression on high-fat diet. Conse-
quently, the unaffected lipogenesis resulted in similar hepatic
lipid content between control ASO and PGC-1b ASO groups.These findings raise the possibility that fructose can directly
induce the transcriptional activity of SREBP-1 via PGC-1b.
Interestingly, we also found that PGC-1b ASO treatment
increased plasma cholesterol concentrations. We did not
observe any increases in the expression of SREBP-2, a key tran-
scriptional regulator of cholesterol biosynthesis, or in the
SREBP-2 responsive genes HMGCoAR or LDL-R following
PGC-1b ASO treatment. These data suggest that cholesterol
biosynthesis in liver and LDL uptake from plasma by liver were
unlikely to be responsible for the observed increases in plasma
cholesterol in the PGC-1b ASO-treated groups. Consistent
with these observations, we found that reduction in PGC-1b
expression in primary rat hepatocytes had no effect on the incor-
poration rate of [14C]acetic acid into sterol. We next investigated
the effects of PGC-1b knockdown on the expression of LXRa
and its target genes. LXRa has been shown to be an important
regulator of cholesterol (Kalaany et al., 2005) and is coactivated
by PGC-1s (Lin et al., 2005). Although we found that LXRa
expression was not different in the four groups, hepatic
CYP7A1 expression was decreased in both PGC-1b ASO-
treated groups. Since CYP7A1 is responsible for the rate-
controlling step in the bile acid synthesis pathway, it is likely
that this reduction in CYP7A1 may explain the increased plasma
cholesterol concentrations in the PGC-1b ASO-treated rats.
In conclusion, these data support an important role for PGC-1b
in the pathogenesis of fructose-induced hypertriglyceridemia
and insulin resistance. Furthermore, given recent studies sug-
gesting an important role for increased hepatic de novo lipogen-
esis in the pathogenesis of hypertriglyceridemia and NAFLD
associated with the metabolic syndrome (Petersen et al., 2007),
these data suggest that PGC-1b inhibition may be a therapeutic
target for treatment of this condition.
EXPERIMENTAL PROCEDURES
Animals
All rats were maintained in accordance with the Institutional Animal Care and
Use Committee of Yale University School of Medicine. Healthy male
Sprague-Dawley ratsweighing200 gwere obtained fromCharles River Labo-
ratories and acclimated for 1 week after arrival before initiation of the experi-
ment. Rats received water ad libitum and were maintained on a 12:12 hr light/
dark cycle (lights on at 6:00 a.m.). They received regular rodent chow (60%
carbohydrate, 10% fat, 30% protein calories), a high-fructose diet (66.8%
carbohydrate, 13% fat, 20.2% protein calories, TD.89247) (Harlan Teklad;
Madison,WI), or a high-fat diet (24.0%carbohydrate, 54.8% fat, 21.2%protein
calories, TD.93075) (Harlan Teklad; Madison, WI) three times per week at
a weight of 225 g per week for 4 weeks. Intraperitoneal (i.p.) ASO therapy
was initiated 3 days after commencing the high-fructose diet. All ASOs (control
and PGC-1b) were prepared in normal saline, and the solutions were sterilized
through a 0.2 mmfilter. Rats were dosed with ASO solutions twice per week via
i.p. injection at a dose of 50 mg/kg per week for 4 weeks. During the treatment
period, bodyweightwasmeasuredweekly. After 14–20days of ASO treatment,
rats underwent the placement of jugular venous and carotid artery catheters.
They recovered their presurgical weights by 5–7 days after the operation.
Selection of Rat PGC-1b ASOs
To identify rat PGC-1b ASO inhibitors, rapid throughput screens were
performed in vitro as described previously (Qu et al., 1999). In brief, 80 ASOs
were designed to the rat PGC-1bmRNA sequences, and initial screens identi-
fied several potent and specific ASOs, all of which targeted a binding sitewithin
the coding region of the PGC-1b mRNAs. After extensive dose-response
characterization, the most potent ASO from the screen was chosen: ISIS-
384891, with the following sequence: 5-CTGGAAGTCCTGGGAGACAC-3.Cell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc. 261
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GGTTCCTCC-3, and does not have perfect complementarity to any known
gene in public databases.
Hyperinsulinemic-Euglycemic Clamp Studies
After 4 weeks of the assigned diet, rats were fasted overnight. The following
morning, the clamp study began with a prime (1 mg/kg for 8 min) of
[6,6-2H]glucose followed by a continuous infusion at a rate of 0.1 mg/kg per
minute for 2 hr to assess the basal glucose turnover. After the basal period,
the hyperinsulinemic-euglycemic clamping was conducted for 140 min with
a primed/continuous infusion of human insulin (400 mU/kg prime for 5 min,
4 mU/kg/min infusion) (Novo Nordisk) and a variable infusion of 20% dextrose
to maintain euglycemia (approximately 100 mg/dl). The 20% glucose was
enriched with [6,6-2H]glucose to approximately 2.5% to match the enrichment
in the plasma achieved after the basal period. A 30 mCi bolus of 2-deoxy-d-
[1-14C]glucose (PerkinElmer) was injected 120 min into the clamp to estimate
the rate of insulin-stimulated tissue glucose uptake. At the end of the clamp,
rats were anesthetized with pentobarbital sodium injection (150 mg/kg), and
all tissues were taken within 4 min, frozen immediately with the use of liquid
N2-cooled aluminum tongs, and stored at 80C for subsequent analysis.
Biochemical Analysis and Calculations
Plasma glucose was analyzed during the clamping with the use of 10 ml plasma
by a glucose oxidase method on a Beckman Glucose Analyzer II (Beckman
Coulter). Plasma insulin and adiponectin were measured by RIA using kits
from Linco. Plasma leptin was measured using the LINCOplex Assay system
(Linco). Plasma RBP4 was measured using EIA Kit from ALPCO.
Plasma fatty acid concentrations were determined using an acyl-CoA
oxidase-based colorimetric kit (Wako). To determine the enrichment of
[6,6-2H]glucose in plasma, samples were deproteinized with five volumes of
100% methanol, dried, and derivatized with 1:1 acetic anhydride/pyridine to
produce the pentacetate derivative of glucose. The atom percentage enrich-
ment of glucoseM + 2 was then measured by gas chromatographic/mass
spectrometric analysis using a Hewlett-Packard 5890 Gas Chromatograph
interfaced to a Hewlett-Packard 5971A Mass Selective Detector operating in
the electron ionization mode (Hundal et al., 2002). GlucoseM + 2 enrichment
was determined from the m/z ratio 202:200. Rates of basal and insulin-stimu-
lated whole-body glucose turnover were determined as the ratio of the rate of
[6,6-2H]glucose infusion (mg/kg per min) to the atom percentage excess
glucoseM + 2 (%) in the plasma. This rate was corrected by subtraction of
the rate of [6,6-2H]glucose infusion. HGP was determined by subtraction of
the glucose infusion rate from the rate of total glucose appearance. For the
determination of muscle andWAT [14C]2-deoxyglucose-6-phosphate content,
tissue samples were homogenized, and the supernatants were subjected to
an ion-exchange column to separate [14C]2-deoxyglucose-6-phosphate
from 2-deoxyglucose as previously described (Youn and Buchanan, 1993).
Tissue Lipid Measurement
The DAG extraction and analysis were performed as previously described
(Yu et al., 2002). After purification, DAG fractions were dissolved in meth-
anol/H2O (1:1, vol/vol) and subjected to liquid chromatography-tandem
mass spectrometry (LC/MS/MS) analysis. A Turbo Ion Spray source was inter-
faced with an API 3000 Tandem Mass Spectrometer (Applied Biosystems) in
conjunction with two PerkinElmer Series 200 Micro Pumps and a PerkinElmer
Series 200 Autosampler. Total DAG content is expressed as the sum of indi-
vidual species. Tissue triglyceride was extracted by the method of Bligh and
Dyer (Bligh and Dyer, 1959) and measured with the use of a DCL Triglyceride
Reagent (Diagnostic Chemicals Ltd.).
Total RNA Preparation and RT-qPCR Analysis
Total RNA was extracted from liver samples using the RNeasy Kit (QIAGEN).
RNA was reverse-transcribed into cDNA with the use of M-MuLV Reverse
Transcriptase (New England Biolabs). The abundance of transcripts was
assessed by real-time PCR on an Applied Biosystems 7500 Real-Time PCR
System (Applied Biosystems) with a SYBR Green detection system. For
each run, samples were run in duplicate for both the gene of interest and actin.
The expression data for each gene of interest and actin were normalized for the262 Cell Metabolism 9, 252–264, March 4, 2009 ª2009 Elsevier Inc.efficiency of amplification, as determined by a standard curve included on
each run (Pfaffl, 2001).
mtDNA Content
Total DNA was isolated from 20 mg of each basal liver using a QIAamp DNA
Micro Kit (QIAGEN). Fifty nanograms of total DNA was used as a template in
20 ml PCR reaction using an Applied Biosystems 7500 Real-Time PCR System
with a SYBR Green detection system against ATP6 (mitochondrial encoded
gene) and b-actin (nuclear encoded gene). mtDNA copy number was
presented as a ratio of ATP6 to b-actin as previously described (Bhat and Epel-
boym, 2004).
Determination of Fatty Acid and Sterol Synthesis in Transfected Rat
Hepatocytes In Vitro
Primary rat hepatocyteswere isolated as previously described and plated onto
collagen-coated 25 cm2 flasks for 60 mm plates for the synthesis measure-
ment. Hepatocytes were treated with ASO (150 nM) and Lipofectin (Invitrogen)
mixture for 4 hr in serum-free Williams’ Media E (Invitrogen). ASO and Lipofec-
tin were mixed in a ratio of 3 mg of Lipofectin for every 1 ml of 100 nM ASO
concentration. After 4 hr, ASO reaction mixture was replaced with normal
maintenance media (Williams’ Media E with 10% FBS and 10 nM insulin).
The cells were incubated under normal conditions for 20–24 hr, and then fatty
acid and sterol synthesis (incorporation of [14C]acetic acid into fatty acid and
sterol) were measured as described previously (Yu et al., 2005).
Western Blotting
For SREBP-1 quantification, nuclear protein was extracted using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce). The protein extracts
were resolved by SDS-PAGE using 4%–12% gradient gel (Invitrogen) and
electroblotted onto PVDF membrane (DuPont) with the use of a wet transfer
cell (Bio-Rad). The membrane was then blocked for 2 hr at room temperature
in PBS-Tween (10 mmol/l NaH2PO4, 80 mmol/l Na2HPO4, 0.145 mol/l NaCl,
and 0.1% Tween-20, pH 7.4) containing 5% (weight/vol) nonfat powder dried
milk, washed twice, and incubated overnight with rabbit anti-peptide antibody
against SREBP-1 (H-160; Santa Cruz Biotechnology, Inc.) diluted 1:100 in
rinsing solution. After further washings, membranes were incubated with
HRP-conjugated IgG fraction of goat anti-rabbit IgG (Bio-Rad), diluted
1:5,000 in PBS-Tween, for 2 hr. These blots were stripped and reblotted with
rabbit anti-retinoblastoma-associated protein (Rb) IgG to normalize for varia-
tions in protein loading. Blots were scanned and analyzed with ImageJ (NIH).
A separate group of rats was used to assess the impact of hepatic DAG
accumulation and PKC3 quantification. These rats were treated exactly as
described above and underwent 20 min of hyperinsulinemic-euglycemic
clamping after a basal infusion. Tissues were harvested in situ immediately
at the end of the clamping. For PKC3 quantification, plasma membrane and
cytosol protein were extracted using ProteoExtract Native Membrane Protein
Extraction Kit (Calbiochem). Western blotting was performed as described
above. Twenty micrograms of homogenized samples were blotted on PVDF
membranes. The membrane was incubated overnight with rabbit anti-peptide
antibody against PKC3 (1:1000; Santa Cruz Biotechnology, Inc.). These blots
were stripped and reblotted with plasma membrane marker, mouse sodium
potassium ATPase IgG (abcam), and rabbit anti-actin IgG to normalize for vari-
ations in protein loading. The polyclonal PGC-1b antibodies were a kind gift
provided by Doctor B. Spiegelman, Harvard Medical School, and purchased
from Novus.
Chromatin Immunoprecipitation Assay
ChIP assays were performed according to the procedure described previously
(Gosmain et al., 2005; Deng et al., 2007) with minor modifications using Cham-
pionChIP One-Day Kit (SABiosciences). Fresh liver samples (300 mg) were
minced and treated for 15minwith 10ml formaldehyde (1%final concentration
in DMEM) at room temperature. Cross linking was stopped by the addition of
glycine to a final concentration of 125 mM. Chromatin extracts were prepared
from tissue homogenates and further fragmented by sonication. The sonicated
chromatin was first precleared for 1 hr with protein G agarose/salmon sperm
DNA beads (Millipore). After centrifugation, supernatants were incubated
overnight at 4C with 4 mg of an anti-SREBP-1 antibody (H-160; Santa-Cruz
Biotechnology), 4 mg of anti-LXRa/b antibody (S-20; Santa-Cruz
Cell Metabolism
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complex was bound to protein A-Sepharose beads during 1 hr at 4C and
washed in low-salt buffer, high-salt buffer, LiCl buffer, and Tris-EDTA buffer.
Proteins were eliminated using Proteinase K for 30 min at 45C. The DNA
was purified and used as a template for PCR. The sets of PCR primers used
for the analysis of the rat SREBP-1c proximal promoter were 5-
TGGTTGCCTGTGCGGCAG-3 (SREBP-1c-Pro-S) and 5-TCAGGCCCCGC
CAGGCTTTAA-3 (SREBP-1c-Pro-AS). Real-time PCR analyses were per-
formed using 7500 Real-Time PCR System (Applied Biosystems). The PCR
amplification products were analyzed on ethidium bromide-stained 2%
agarose gels.
Akt Activity
Liver Akt activity was measured using a commercially available kit (Assay
Designs).
Calpain Activity
Calpain activity in WAT was determined using a commercially available kit
(Calbiochem).
Statistics
Values are expressed as mean ± SEM. The significance of the differences in
mean values among different treatment groups was evaluated by two-tailed
Student’s t tests or one-way ANOVA followed by post hoc analysis using the
Tukey’s Honestly Significant Differences (HSD) test. P values less than 0.05
were considered significant.
SUPPLEMENTAL DATA
Supplemental Data include two tables andonefigure andcanbe foundonline at
http://www.cell.com/cellmetabolism/supplemental/S1550-4131(09)00036-9.
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